WHO Expert Committee on Biological Standardization: highlights of the 50th meeting, October 1999.
Biological medicines, which include vaccines, blood products and biological therapeutics, have historically played a dominant role in improving world health and are expected to make an increasingly important contribution to public health in the 21st century. Recent scientific and biotechnological developments have opened the way to novel products, new production methods and to highly sensitive assay procedures. However, the nature of biologicals, and especially new vaccines, blood products and therapeutics, raises particular questions regarding their standardization and quality control. These relate both to efficacy and to safety not only for the individual recipient but also for the population at large. Such advances highlight the complex issues surrounding standardization and control of biologicals, issues that need to be addressed on an international level.
Wood
D J
DJ
Division of Virology, National Institute of Biological Standards and Controls, South Mimms, Potters Bar, Herts, EN6 3QG, UK.
Padilla
A
A
Griffiths
E
E
D001685:Biological Factors / Q000592:standards*; D001769:Blood; D017408:Guidelines as Topic; D006801:Humans; D017096:Prion Diseases / Q000517:prevention & control; D011328:Prions / Q000302:isolation & purification; D011786:Quality Control; D012015:Reference Standards; D014612:Vaccines / Q000592:standards*; D018074:Vaccines, Conjugate / Q000592:standards; D014944:World Health Organization
D001685:Biological Factors; D011328:Prions; D014612:Vaccines; D018074:Vaccines, Conjugate